Summary: A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. There is no consensus on the treatment of ticlopidine-induced marrow aplasia. Although many cases are reported to recover with colony-stimulating factors Ticlopidine is a thienopyridine antiplatelet agent that is licensed for the secondary prevention of stroke in patients who do not respond to or are intolerant to aspirin (1). It has also been shown to be effective in cardiovascular and peripheral vascular thrombosis; particularly effective in the prevention of coronary stent thrombosis (1,2). Ticlopidine inhibits ADP-induced platelet aggregation. Its mechanism of action is inhibition of ADP-induced platelet aggregation via binding of its metabolite or metabolites to the low-affinity type 2 purinergic ADP receptors (3). Diarrhea, rash, and neutropenia are frequently reported toxicities due to ticlopidine (4). There are also other hematologic toxicities associated with ticlopidine such as thrombocytopenia, thrombotic thrombocytopenic purpura, and marrow aplasia (3). We report a case of marrow aplasia due to ticlopidine that was successfully treated with cyclosporine.
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A 50-year-old male patient was admitted to our hospital because of fever. He had hypertension and diabetes mellitus that was controlled only with diet for a few years. Hematologic findings were within normal limits before coronary angiography and coronary angioplasty that was performed at another hospital 3 months previously. He was given ticlopidine, amplodipine, acetyl salicylic acid, and nitrates after the procedure. On the tenth day of ticlopidine treatment, fatigue, gingival bleeding, and gingivitis developed. He consulted his physician, but his complaints were ignored and a blood analysis was not performed. On the 40th day of ticlopidine treatment, there was lymphadenopathy in his neck. His white blood cell count was 1.700/mm3. Unfortunately, we could not obtain the exact red blood cell and platelet counts. Bone marrow biopsy was performed with a diagnosis of aplasia. Ticlopidine was withdrawn. He was hospitalized at another hospital. Granulocytemacrophage colony-stimulating factors (GMCSF) and corticosteroids were administered. His white blood cell counts increased to 3,000 to 4,000/mm3 during treatment, but his blood glu-cose levels reached 400 mg/dL. On the 20th day of GMCSF and corticosteroid treatment, he applied to our center. On admittance his body temperature was 39°C, he looked pale, and his physical examination was normal. Hemoglobin count was 10 g/L, and the white blood cell count was 3,400/mm3 with neutrophils numbering 500 to 700/mm3. Atypical mononuclear cells were observed on the peripheral blood smear; platelets were low but sufficient. Marrow aplasia and febrile neutropenia due to ticlopidine treatment were diagnosed. Broad-spectrum antibiotic treatment and oral cyclosporine 4 mg/kg/day were given immediately. The patient strongly objected to insulin therapy for treatment of hyperglycemia, so we excluded corticosteroids from the regimen. Daily blood cell counts and peripheral smears exhibited dramatic improvement. On the tenth day of cyclosporine treatment he was well and all of his hematologic findings were normal: hemoglobin, 15 .4 g/L; white blood cells, 8,100/mm3; platelets, 157,000/mm3. Cyclosporine was discontinued. Bone marrow biopsy performed on the third month of follow-up was normocellular. Chromosome analysis was not performed.
DISCUSSION
Marrow aplasia describes a syndrome with varied etiologies and pathogenetic mechanisms, characterized by a peripheral blood pancytopenia with an empty bone marrow in the absence of neoplastic infiltration or myeloproliferative disease. Drug exposure is the most frequently cited specific etiology for marrow aplasia (5). It is rare, but the most dangerous hematologic side effect of ticlopidine. The pathogenesis of bone marrow toxicity by ticlopidine is unclear. This complication is due to a dose-dependent direct cytotoxic effect in susceptible individuals (6). Granulocyte-macrophage-colony-forming unit (GM-CFU) was found to be slightly decreased in bone marrow culture specimens from patients treated with ticlopidine. An increase in prostaglandin-El (PGE1) synthesis that is directly mediated by ticlopidine may be particularly responsible (7) . Success of corticosteroid treatment in some patients favors this hypothesis.
Although hematologic side effects other than marrow aplasia are rapidly reversible on discontinuation of ticlopidine, marrow aplasia caused by this drug is severe, prolonged, and often fatal due to infections (8-11) . The predisposing factors for ticlopidine-induced marrow aplasia are not known. It usually occurs from 4 weeks to 3 months after initiation of therapy. The bone marrow aplasia in our patient also occured within this period. Age (>65 years old) may be a risk factor for this complication and relates to mortality (8) (9) (10) (11) (12) . The favorable outcome of our young patient supports the relationship between age and mortality.
Therapy of ticlopidine-induced marrow aplasia with corticosteroids or colony-stimulating factors (G-CSF or GM-CSF) or androgens has resulted in poor outcomes with a high mortality rate and a slow recovery of marrow function in surviving patients (8, (11) (12) (13) . However, there are articles praising the effectiveness of growth factors (14-16). Vinod and associates recently reported a rapid and sustained response with cyclosporine and high-dose corticosteroids in a patient with ticlopidine-induced marrow aplasia. They suggest cyclosporine and high-dose corticosteroids as first-line therapy (13) . Our patient also partially responded to colony-stimulating growth factors and corticosteroids, but dramatically recovered solely with oral cyclosporine.
In our center, clopidogrel, a new antiplatelet agent with fewer side effects, is preferred to ticlopidine; however, within the past 6 months, we had two patients with ticlopidine-induced neutropenia and a patient with marrow aplasia,. We think that ticlopidine-induced marrow aplasia may be more frequent than reported. Therefore predisposing factors should be evaluated. In the literature, five of six patients with ticlopidine-induced marrow aplasia who received concurrent calcium channel blockers died (12) . Our patient also received a calcium channel blocker: amplodipine and ticlopidine simultaneously. Although our patient survived, we wonder if there is a casual relationship between these two groups of medications in causation of marrow aplasia. Further observations are needed to support this proposal.
In conclusion, ticlopidine has a serious side effect-marrow aplasia-and should be prescribed only for the patients who are unresponsive or intolerant to aspirin. It is not the first drug of choice for any indication. Every patient receiving ticlopidine therapy should be routinely observed for adverse hematologic side effects. Additional care must be given to the patients who have to take calcium channel blockers and ticlopidine simultaneously. In the case of ticlopidine-induced marrow aplasia unresponsive to other treatment modalities, cyclosporine is an effective choice.
